ReviewInternational wound journal2019
Managing keloid scars: From radiation therapy to actual and potential drug deliveries.
Review in International wound journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- A Tissue-Homologous Keratin-PBA Hydrogel Integrating Rationally Designed Nanomicelles Enables Microenvironment-Adaptive Repair of Chronic Diabetic Wounds.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- LncRNA RNF144A-AS1 increases P300-mediated H4K5 acetylation of PDE4 to promote keloid fibrosis.Biomedical engineering online · 2026Article
- Endothelial system dysregulation underlies keloid development and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- Unlocking Better Keloid Treatment: Corticosteroid, 5-Fluorouracil, and Hyaluronidase vs. Corticosteroid Alone - A Randomized Comparative Study.Health science reports · 2025Article
- Long-Term Outcome of Anterior Chest Keloid Excision Using Intercostal Artery Perforator Propeller Flaps.Aesthetic plastic surgery · 2025Article
- The efficacy of combined adjuvant radiotherapy with surgical excision in the treatment of keloids.Annals of burns and fire disasters · 2025Article
- MicroRNAs Associated with Keloids Identified by Microarray Analysis and In Vitro Experiments.Molecular biotechnology · 2025Article
- Therapeutic Potential of Compounds with High Affinity to BAG2 in Inhibiting Keloid Disease.Biologics : targets & therapy · 2025Article
- Gene Profiling of Circular RNAs in Keloid-prone Individuals and ceRNA Network Construction During Wound Healing.Aesthetic plastic surgery · 2024Article
- Logistic regression analysis of risk factors influencing postoperative keloid scar recurrence.American journal of translational research · 2024Article
- Future Directions About Keloid Scars Based on Pathogenesis and Therapies.Clinical, cosmetic and investigational dermatology · 2024Review
- Acne-induced pathological scars: pathophysiology and current treatments.Burns & trauma · 2024Review
- The Communication from Immune Cells to the Fibroblasts in Keloids: Implications for Immunotherapy.International journal of molecular sciences · 2023Review
- Tissue RNA Sequencing Reveals Novel Biomarkers Associated with Postoperative Keloid Recurrence.Journal of clinical medicine · 2023Article
- Effects of dupilumab on keloid stabilization and prevention.JAAD case reports · 2023Article
- Early outcomes of complete excision followed by immediate postoperative single fractional 10 Gy for anterior chest keloids: A preliminary results.International wound journal · 2023Article
- Surgical Excision of Keloid in the Ear Lobule and Reconstruction with Full-Thickness Graft followed by Injection of PRP and Hyaluronic Acid-A Case Report.Journal of maxillofacial and oral surgery · 2023Article
- Keloid Core Factor CTRP3 Overexpression Significantly Controlled TGF-Disease markers · 2023Article
- Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis.International journal of molecular sciences · 2022Review
- Circular RNA hsa_circ_0057452 facilitates keloid progression by targeting the microRNA-1225-3p/AF4/FMR2 family member 4 axis.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aetiology of keloids is becoming clearer, but many questions remain, including about the most optimal treatment. Current therapies include surgical excision, radiotherapy, and various pharmaceutical drugs. However, none of these drugs are keloid-specific. Moreover, all current interventions are associated with high recurrence rates. Here, we review the pharmaceutical interventions that are currently available. All are based on the fact that keloids are an expanding solid mass with intense chronic inflammation at its advancing edges. Consequently, current pharmaceuticals aim to reduce the mass and/or symptoms of keloids, similar to surgery and radiotherapy. They include chemotherapies, immunotherapies, volume-reducing therapies, and anti-inflammatory therapies. We also describe new advances in keloid pharmaceuticals. They include drugs that were designed to treat systemic diseases such as hypertension or breast cancer but were found to also treat keloids. Furthermore, recent progress in genetic, epigenetic, and stem cell therapies suggests that they could become useful in the keloid field. This review of pharmaceutical advances will hopefully promote additional research and the development of effective and specific pharmaceuticals for keloids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.